Purpose

Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subjects must have a diagnosis of COPD - at their clinical baseline on the day of imaging - must be clinically stable in order to participate in the study. - COPD subjects will be categorized according to the GOLD - Current/Former SmokerSubjects - must have a smoking history ≥ 10 pack years

Exclusion Criteria

  • Dx of asthma - Continuous oxygen use at home - Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging - FEV1 percent predicted less than 25% - Pregnancy or lactation - Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning - Subjects with any implanted device that cannot be verified as MRI compliant will be excluded - Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches - History of congenital cardiac disease, chronic renal failure, or cirrhosis - Inability to understand simple instructions or to hold still for approximately 10 seconds - History of respiratory infection within 2 weeks prior to the MR scan - History of MI, stroke and/or poorly controlled hypertension.

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Crossover Assignment
Intervention Model Description
COPD patients with standard vs study diagnostic methods (imaging procedures)
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
COPD patients - Xe-133
COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
  • Drug: Radioactive Xenon-133 scintigraphy (Active Comparator)
    Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
    Other names:
    • Pilot study
Experimental
COPD patients - Hyperpolarized Xe-129
COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
  • Drug: Hyperpolarized Xenon-129 MRI (Experimental)
    MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
    Other names:
    • Polarean Pilot study

Recruiting Locations

University of Virginia Health System
Charlottesville 4752031, Virginia 6254928 22908
Contact:
Sarah Struchen, RN
434-243-6074
SS8YM@hscmail.mcc.virginia.edu

More Details

Status
Recruiting
Sponsor
University of Virginia

Study Contact

Sarah Struchen, RN
4342436074
SS8YM@hscmail.mcc.virginia.edu

Detailed Description

Hyperpolarized Xenon-129 MRI has been developed by a number of techniques for imaging the lung that provide information about various aspects of lung function and structure. The main objective of this pilot study is to test and optimize the imaging parameters for a future industry sponsored clinical trial. The goal of the future trial is to determine the concordance between hyperpolarized xenon-129 ventilation MR imaging and nuclear medicine ventilation imaging (Gold Standard). In this study we will test the imaging parameters and techniques. We will directly compare human ventilation lung images in subjects with COPD, using nuclear medicine ventilation imaging with Xenon-133 gas scintigraphy versus hyperpolarized xenon-129 gas MRI. Our hypothesis is that current Xe-133 scintigraphy, which uses a radioactive gas (Xe-133) and produces a projection image of the lungs with relatively poor resolution, will not be able to detect small lung ventilation obstructions, which can be detected using hyperpolarized Xe-129 gas MRI.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.